Mersana Therapeutics Stock (NASDAQ:MRSN)
Previous Close
$2.22
52W Range
$1.22 - $6.28
50D Avg
$2.05
200D Avg
$2.72
Market Cap
$274.24M
Avg Vol (3M)
$1.03M
Beta
1.48
Div Yield
-
MRSN Company Profile
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
MRSN Performance
Peer Comparison
| Ticker | Company |
|---|---|
| PLRX | Pliant Therapeutics, Inc. |
| XFOR | X4 Pharmaceuticals, Inc. |
| CGEM | Cullinan Oncology, Inc. |
| RVMD | Revolution Medicines, Inc. Warrant |
| VRDN | Viridian Therapeutics, Inc. |
| MRUS | Merus N.V. |
| RCUS | Arcus Biosciences, Inc. |
| DAWN | Day One Biopharmaceuticals, Inc. |
| HOOK | HOOKIPA Pharma Inc. |
| CERE | Cerevel Therapeutics Holdings, Inc. |
| RLAY | Relay Therapeutics, Inc. |
| REPL | Replimune Group, Inc. |
| SNDX | Syndax Pharmaceuticals, Inc. |
| TERN | Terns Pharmaceuticals, Inc. |
| INZY | Inozyme Pharma, Inc. |
| ABOS | Acumen Pharmaceuticals, Inc. |
| PTGX | Protagonist Therapeutics, Inc. |
| KURA | Kura Oncology, Inc. |
| AMLX | Amylyx Pharmaceuticals, Inc. |